{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chickenpox/management/immunocompromised/","result":{"pageContext":{"chapter":{"id":"dac00668-b032-569c-8b5a-260c2f1625b3","slug":"immunocompromised","fullItemName":"Scenario: Immunocompromised","depth":2,"htmlHeader":"<!-- begin field e5ffabb1-b89a-47df-a6e2-d4cc69abdaf9 --><h2>Scenario: Immunocompromised person</h2><!-- end field e5ffabb1-b89a-47df-a6e2-d4cc69abdaf9 -->","summary":"Covers the management of an immunocompromised person with chickenpox.","htmlStringContent":"<!-- begin item 4f8d297a-8e1a-42b5-a023-fc96eb72531f --><!-- begin field 51fe4f0c-2ec5-4fa8-bcc8-acbc0159b913 --><p>From age 1 month onwards.</p><!-- end field 51fe4f0c-2ec5-4fa8-bcc8-acbc0159b913 --><!-- end item 4f8d297a-8e1a-42b5-a023-fc96eb72531f -->","topic":{"id":"5d1b7a44-f7ff-52e9-a218-c53ecadb0e4c","topicId":"4960f8a4-0140-4c3b-9bd0-b1ac6fccd648","topicName":"Chickenpox","slug":"chickenpox","lastRevised":"Last revised in August 2018","chapters":[{"id":"fe0450ab-ddfd-5960-bb47-b986d9cc6059","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ff90f80f-13d4-5732-8d09-9c5566ce6ec2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"16ae9969-1384-5b7b-aff0-1ac19aeee530","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"10059b43-4a23-59cf-8f5f-31f8d5e8e3c9","slug":"changes","fullItemName":"Changes"},{"id":"5f0098ae-9d37-5658-9379-66477733f220","slug":"update","fullItemName":"Update"}]},{"id":"9d70228e-0283-5d34-a4af-5237097d0a02","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fa1d46ea-9d63-5d1a-b60c-9b96e87f802c","slug":"goals","fullItemName":"Goals"},{"id":"4e21e939-92fd-555c-a175-93b8a626169a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ea18d1e8-0bdd-542f-a985-2952ecabca2d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5d911096-5b50-551b-a17a-cff3070315b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"601f7c68-386e-5474-96f1-d6239bd81750","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"305e8fa8-8eb6-5b69-a902-93019e0c2c17","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bb9b11dc-3295-5e2b-9798-37bb8b6ebbc0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"145f102c-4e0f-52c9-8b3b-e0b5c6eb112e","slug":"definition","fullItemName":"Definition"},{"id":"9f4d0cad-78a8-568f-831e-8878d2f4bfd3","slug":"transmission","fullItemName":"Transmission"},{"id":"5691920a-f618-5a98-ab32-417dfc782db1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"eb6a66b5-2006-5968-a97d-52de72842cbf","slug":"complications","fullItemName":"Complications"}]},{"id":"a3eb8e9b-cdd9-5243-8353-09aac3fdc322","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff9f70a8-0c29-5357-946d-bbca67eafbbf","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b651c5b4-34df-5480-b05d-909c9023a7a5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3844af91-e26b-515e-a645-9725d2f54810","fullItemName":"Management","slug":"management","subChapters":[{"id":"7700c175-994a-51d5-a2d0-36eb7478e2c1","slug":"child-or-adult","fullItemName":"Scenario: Child or adult"},{"id":"f6a62aa2-354d-5eee-a868-fb5d162115ef","slug":"pregnant-woman","fullItemName":"Scenario: Pregnant woman"},{"id":"c659257f-8875-5440-ae24-57c071cf226c","slug":"breastfeeding-woman","fullItemName":"Scenario: Breastfeeding woman"},{"id":"499e6045-af39-5bc4-952b-edcb6b29144f","slug":"neonate","fullItemName":"Scenario: Neonate"},{"id":"dac00668-b032-569c-8b5a-260c2f1625b3","slug":"immunocompromised","fullItemName":"Scenario: Immunocompromised"},{"id":"072ae3a5-9cf4-5233-bca1-2d46e53de42b","slug":"exposure-to-chickenpox","fullItemName":"Scenario: Exposure to chickenpox"}]},{"id":"fa12b54d-0c95-5ee8-8884-219ac7a9dd2a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2d64426-afb7-5590-998d-3ed0d13b78d2","slug":"chlorphenamine","fullItemName":"Chlorphenamine"},{"id":"17d5cf92-3449-52d5-932c-f1b770061787","slug":"aciclovir","fullItemName":"Aciclovir"}]},{"id":"95550d9e-6be2-5a94-924a-c4c2f8e7dbe4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"880099bb-bff8-543e-a1e8-267413ef45b9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c80905f1-b771-5170-8be8-c1bcee935552","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6bf66548-b486-53e1-bce7-d9bb45af9bea","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"52168b40-dab0-5afb-9662-bb28014b5734","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5fa2da47-e83a-5886-9c1b-c6ae4e97a0a7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"769ea126-78ac-540c-a1c9-38446d44e22e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"87e1772a-0cd8-5e0c-ad7a-b676a65171bb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3844af91-e26b-515e-a645-9725d2f54810","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"3ba52f1f-0e82-5188-a658-1a432883fbc2","slug":"managing-an-immunocompromised-person","fullItemName":"Managing an immunocompromised person","depth":3,"htmlHeader":"<!-- begin field 89fb84cf-41b8-436c-9f30-8e422de8a4b4 --><h3>How should I manage an immunocompromised person with chickenpox?</h3><!-- end field 89fb84cf-41b8-436c-9f30-8e422de8a4b4 -->","summary":null,"htmlStringContent":"<!-- begin item 5b42d53b-63c5-4369-a1ab-559001ca9966 --><!-- begin field 310d1dc4-b43d-4fee-930c-f67b107e6165 --><ul><li>Admit the person to hospital if serious complications (for example pneumonia or encephalitis) are suspected.</li><li>If hospital admission is not required:<ul><li>Seek immediate specialist advice regarding confirming the diagnosis of chickenpox and further management.</li><li>Offer <a class=\"topic-reference internal-reference\" href=\"/topics/chickenpox/management/immunocompromised/#treating-symptoms-in-immunocompromised-people\">symptomatic treatment</a>. </li><li>Give <a class=\"topic-reference internal-reference\" href=\"/topics/chickenpox/management/immunocompromised/#advice-for-an-immunocompromised-person-with-chickenpox\">advice</a> about contact with other people and when to seek medical advice.</li><li>If a high temperature develops (particularly after initial improvement) with redness and pain surrounding the chickenpox lesions, consider bacterial superinfection and manage accordingly. </li></ul></li><li>For advice on how to manage an immunocompromised person who has been exposed to but not yet developed chickenpox, see the <a class=\"topic-reference internal-reference\" href=\"/topics/chickenpox/management/exposure-to-chickenpox/\">Scenario: Exposure to chickenpox</a>.</li></ul><!-- end field 310d1dc4-b43d-4fee-930c-f67b107e6165 --><!-- end item 5b42d53b-63c5-4369-a1ab-559001ca9966 -->","subChapters":[{"id":"174cc296-cacb-5bef-b672-826c6becf26c","slug":"basis-for-recommendation-03c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b512d3c0-4261-468e-add9-d16293e78a4e --><h4>Basis for recommendation</h4><!-- end field b512d3c0-4261-468e-add9-d16293e78a4e -->","summary":null,"htmlStringContent":"<!-- begin item 03caf81e-4dd0-4498-ba0e-36a12e2fcede --><!-- begin field bf773c32-2203-4a3a-b323-7c2ca4a42359 --><h5>Admission to hospital</h5><ul><li>This recommendation is pragmatic and is based on what CKS considers to be good clinical practice. </li><li>Immunocompromised people with chickenpox are at increased risk of developing complications (such as pneumonia, encephalitis, hepatitis, and disseminated intravascular coagulopathy) as a result of varicella zoster virus affecting their internal organs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">CDC, 2016</a>].</li></ul><h5>Seeking specialist advice</h5><ul><li>CKS recommends seeking specialist advice on the management of immunocompromised people with chickenpox because of the increased risk of severe disease and <a class=\"topic-reference internal-reference\" href=\"/topics/chickenpox/background-information/complications/#immunocompromised-people\">complications</a> in this group, and the need for close monitoring [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>].</li><li>Chickenpox may be more difficult to diagnose in immunocompromised people as they may have an atypical rash with more lesions (which can be haemorrhagic). The duration of illness may also be increased compared with an immunocompetent person [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">CDC, 2016</a>].<ul><li>Even immunocompromised people who have received varicella-zoster immunoglobulin prophylaxis may develop severe or fatal varicella. Immunocompromised people should be carefully monitored and given aciclovir at the first sign of illness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>].</li></ul></li></ul><h5>Symptomatic treatment</h5><ul><li>This recommendation is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Gould, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BMJ Best Practice, 2016</a>] and what CKS considers to be good clinical practice.</li></ul><h5>Advice about contact and seeking medical advice</h5><ul><li>This recommendation is pragmatic, based on what CKS considers to be good clinical practice.</li></ul><!-- end field bf773c32-2203-4a3a-b323-7c2ca4a42359 --><!-- end item 03caf81e-4dd0-4498-ba0e-36a12e2fcede -->","subChapters":[]}]},{"id":"975102d5-13b7-5bee-8033-bc2ff9440ef0","slug":"advice-for-an-immunocompromised-person-with-chickenpox","fullItemName":"Advice for an immunocompromised person with chickenpox","depth":3,"htmlHeader":"<!-- begin field f71cd440-2e4f-4894-a31b-4a993f481020 --><h3>What advice should I give an immunocompromised person with chickenpox?</h3><!-- end field f71cd440-2e4f-4894-a31b-4a993f481020 -->","summary":null,"htmlStringContent":"<!-- begin item 67fa4178-cb54-4f5e-b61d-1116e93bb472 --><!-- begin field 4bc19972-f519-405d-bfbf-9fc4c5e42fc6 --><ul><li><strong>Advise the following simple measures to help alleviate symptoms:</strong><ul><li>Encourage adequate fluid intake to avoid dehydration.</li><li>Dress appropriately to avoid overheating or shivering.</li><li>Wear smooth, cotton fabrics.</li><li>Keep nails short to minimize damage from scratching.</li></ul></li><li><strong>Advise that the most infectious period is usually 1–2 days before the rash appears, </strong>but infectivity continues until all the lesions have crusted over (this may be prolonged in immunocompromised people):<ul><li>During this time, advise a person with chickenpox to avoid contact with:<ul><li>Other people who are immunocompromised (for example those receiving cancer treatment or high doses of oral steroids, or those with conditions that reduce immunity).</li><li>Pregnant women.</li><li>Infants aged 4 weeks or less.</li></ul></li><li>Advise that children with chickenpox should be kept away from school or nursery until all vesicles have crusted over.</li></ul></li><li><strong>Inform the person to seek urgent medical advice if their condition deteriorates or they develop <a class=\"topic-reference internal-reference\" href=\"/topics/chickenpox/background-information/complications/\">complications</a>. </strong>Parents of young children with chickenpox should be particularly aware of:<ul><li>Bacterial superinfection — manifesting as sudden high grade pyrexia (often after initial improvement), erythema and tenderness surrounding the original chickenpox lesions.</li><li>Dehydration — encourage and monitor fluid intake and seek medical attention if signs of dehydration develop (for example reduced urine output, lethargy, cold peripheries, reduced skin turgor).</li></ul></li></ul><!-- end field 4bc19972-f519-405d-bfbf-9fc4c5e42fc6 --><!-- end item 67fa4178-cb54-4f5e-b61d-1116e93bb472 -->","subChapters":[{"id":"8e80cef2-5111-5d44-b348-7cce8042fd97","slug":"basis-for-recommendation-d3b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3f0a2776-8041-4ef7-9a99-0891a14e9e3c --><h4>Basis for recommendation</h4><!-- end field 3f0a2776-8041-4ef7-9a99-0891a14e9e3c -->","summary":null,"htmlStringContent":"<!-- begin item d3b777eb-e549-4343-a05f-2d8080b352fb --><!-- begin field 02337ad2-06b5-41ba-b655-2450adba4a20 --><h5>Self-care measures</h5><ul><li>The recommendations on self-care measures for symptomatic relief are based on review articles covering the management of chickenpox infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Allen, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BMJ Best Practice, 2016</a>].</li></ul><h5>Advice on contacts</h5><ul><li>This recommendation is based on information on the infectious period of chickenpox and groups at increased risk of complications from chickenpox in <em>Immunisation against infectious disease</em>: 'the Green book', published by Public Health England [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2015</a>], information on chickenpox from the US Centers for Disease Control and Prevention [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">CDC, 2016</a>],<strong> </strong>and a guideline from the Royal College of Obstetricians and Gynaecologists: <em>Chickenpox in pregnancy</em><strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">RCOG, 2015</a>].</li><li>The recommendation on advice on exclusion from school and nursery is based on the Public Health England document <em>Guidance on infection control in schools and other childcare settings </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">PHE, 2016a</a>].<strong> </strong></li></ul><h5>Seeking medical advice</h5><ul><li>This recommendation is pragmatic and is based on what CKS considers to be good clinical practice.</li><li>The advice to bear in mind bacterial superinfection and dehydration as potential complications is extrapolated from the National Institute for Health and Care Excellence guideline: <em>Fever in under 5's: assessment and initial management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">NICE, 2013</a>], expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BMJ Best Practice, 2016</a>], and a case review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Sturgeon et al, 2015</a>].</li></ul><!-- end field 02337ad2-06b5-41ba-b655-2450adba4a20 --><!-- end item d3b777eb-e549-4343-a05f-2d8080b352fb -->","subChapters":[]}]},{"id":"5ffb0faf-bb8a-5075-90cb-f96aa5e1830a","slug":"treating-symptoms-in-immunocompromised-people","fullItemName":"Treating symptoms in immunocompromised people","depth":3,"htmlHeader":"<!-- begin field 668ba164-e42c-4e58-9949-f844c28b16b0 --><h3>How should I treat symptoms in an immunocompromised person?</h3><!-- end field 668ba164-e42c-4e58-9949-f844c28b16b0 -->","summary":null,"htmlStringContent":"<!-- begin item 3402391b-660c-43c7-b64a-77f42fce8d88 --><!-- begin field dd15165d-f7b6-48ad-8e27-03b280ec3960 --><ul><li>Consider offering:<ul><li>Paracetamol if pain or fever are causing distress (avoid nonsteroidal anti-inflammatory drugs). Note that oral paracetamol is not licensed for use in children under 2 months of age.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>.</li></ul></li><li>Topical calamine lotion to alleviate itch.</li><li>Chlorphenamine to treat itch associated with chickenpox for people aged 1 year and above. </li></ul></li></ul><!-- end field dd15165d-f7b6-48ad-8e27-03b280ec3960 --><!-- end item 3402391b-660c-43c7-b64a-77f42fce8d88 -->","subChapters":[{"id":"e96cacf8-4827-5749-80a7-579aad87c2ff","slug":"basis-for-recommendation-2ea","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 54b8812b-fc49-47e3-8090-3d7e099ed5b0 --><h4>Basis for recommendation</h4><!-- end field 54b8812b-fc49-47e3-8090-3d7e099ed5b0 -->","summary":null,"htmlStringContent":"<!-- begin item 2ea9929e-068c-4594-8edc-8d1388bacd24 --><!-- begin field 1b02f2e0-694e-48c9-9e89-930a4a21568a --><h5>Paracetamol and ibuprofen</h5><ul><li>The recommendation to use paracetamol for pain or fever is based on a guideline from the National Institute for Health and Care Excellence (NICE): <em>Fever in under 5's: assessment and initial management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">NICE, 2013</a>]<em> </em>and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Gould, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BMJ Best Practice, 2016</a>]. The information on licensing for children less than 2 months of age is based on the British National Formulary for Children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BNF for Children, 2017</a>].</li><li>CKS has not recommended the use of nonsteroidal anti-inflammatory drugs (NSAIDs) because of concerns that use of NSAIDs in children with varicella is associated with an increased risk of severe skin and soft tissue infections (usually caused by group A streptococcus and <em>Staphylococcus aureus</em>) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">UKMi, 2016</a>]. This is supported by expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Gould, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BMJ Best Practice, 2016</a>]. <ul><li>A literature review by UK Medicines Information found a number of cohort and case-control studies and case series suggesting an association between use of NSAIDs in children with chickenpox and severe skin reactions. Although the confounding factor of the increased likelihood of NSAIDs being required for children with severe cases of chickenpox or complications was noted, on the basis of the available evidence the authors recommended avoiding NSAIDs in children with chickenpox. Paracetamol was recommended as the preferred alternative treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">UKMi, 2016</a>]. </li><li>The risk of skin reactions in adults with chickenpox using NSAIDs is unclear as most of the available trials involved children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">UKMi, 2016</a>]. Until further evidence is available, CKS recommends avoiding NSAIDs such as ibuprofen in adults with chickenpox, in line with expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Gould, 2014</a>].</li></ul></li></ul><h5>Calamine lotion</h5><ul><li>Calamine lotion is thought to relieve itch by evaporating from the skin to induce a cooling effect [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Allen, 2006</a>].</li><li>CKS found no evidence on the use of calamine lotion to treat itch in chickenpox, however it is considered to be an option as it is recommended by the authors of some review articles and there is anecdotal evidence to support its use [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Allen, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Tebruegge et al, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Gould, 2014</a>]. Some experts state that it can dry the skin and increase itch [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">BMJ Best Practice, 2016</a>].  </li></ul><h5>Antihistamines</h5><ul><li>There is very limited evidence to support the use of topical or systemic antihistamines in relieving pruritus in people with chickenpox. Expert opinion is divided, but some experts find chlorphenamine useful from clinical experience. Piriton<sup>®</sup>, but not generic chlorphenamine, is licensed for the symptomatic relief of itching due to chickenpox [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">ABPI, 2016a</a>].<ul><li>Chlorphenamine should not be given to those less than 1 year of age as it is not licensed for use in this age group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">ABPI, 2016a</a>].</li></ul></li><li>In a literature review, only one poor-quality randomized trial was found that investigated the effect of antihistamines in chickenpox [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chickenpox/references/\">Tebruegge et al, 2006</a>]. CKS found no other randomized trials on the effect of antihistamines (including chlorphenamine) in people with chickenpox.</li></ul><h5>Topical crotamiton and colloidal oatmeal bath additives</h5><ul><li>CKS found no evidence to justify the use of topical crotamiton and colloidal oatmeal bath additives in chickenpox.</li></ul><!-- end field 1b02f2e0-694e-48c9-9e89-930a4a21568a --><!-- end item 2ea9929e-068c-4594-8edc-8d1388bacd24 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}